Gold Nanoparticle Aggregates Functionalized with Cyclic RGD Peptides for Targeting and Imaging of Colorectal Cancer Cells

The active targeting strategy has emerged as a promising approach to achieve selectivity in nanobiotechnology applications. Peptides are particularly suited as targeting moieties because the multiv...

[1]  P. Pontisso,et al.  PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. , 2019, Materials science & engineering. C, Materials for biological applications.

[2]  L. Litti,et al.  Predictions on the SERS enhancement factor of gold nanosphere aggregate samples. , 2019, Physical chemistry chemical physics : PCCP.

[3]  Gaoxing Su,et al.  Effects of Protein Corona on Active and Passive Targeting of Cyclic RGD Peptide-Functionalized PEGylation Nanoparticles. , 2018, Molecular pharmaceutics.

[4]  Reynaldo Villalonga,et al.  Hybrid Decorated Core@Shell Janus Nanoparticles as a Flexible Platform for Targeted Multimodal Molecular Bioimaging of Cancer. , 2018, ACS applied materials & interfaces.

[5]  Yinsong Wang,et al.  Reactive Oxygen Species-Responsive Nanoparticles Based on PEGlated Prodrug for Targeted Treatment of Oral Tongue Squamous Cell Carcinoma by Combining Photodynamic Therapy and Chemotherapy. , 2018, ACS applied materials & interfaces.

[6]  C. van Nostrum,et al.  Insights into maleimide‐thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Yaqing Feng,et al.  A novel amphiphilic fluorescent probe BODIPY–O-CMC–cRGD as a biomarker and nanoparticle vector , 2018, RSC advances.

[8]  H. Harashima,et al.  Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. , 2018, International journal of pharmaceutics.

[9]  Kwangmeyung Kim,et al.  Comparison of in vivo targeting ability between cRGD and collagen‐targeting peptide conjugated nano‐carriers for atherosclerosis , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  A. Rosato,et al.  Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide , 2017, Advanced healthcare materials.

[11]  Eun Seong Lee,et al.  Extremely small-sized globular poly(ethylene glycol)-cyclic RGD conjugates targeting integrin αvβ3 in tumor cells. , 2017, International journal of pharmaceutics.

[12]  J. Popp,et al.  Recent progress in surface-enhanced Raman spectroscopy for biological and biomedical applications: from cells to clinics. , 2017, Chemical Society reviews.

[13]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[14]  R. Snyders,et al.  Silver nanoparticles functionalized with a fluorescent cyclic RGD peptide: a versatile integrin targeting platform for cells and bacteria , 2016 .

[15]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[16]  S. Sivasubramanian,et al.  Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in bresat cancer cells: an improved nanomedicine strategies , 2016, Scientific Reports.

[17]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[18]  Tianfeng Chen,et al.  Tailoring Particle Size of Mesoporous Silica Nanosystem To Antagonize Glioblastoma and Overcome Blood-Brain Barrier. , 2016, ACS applied materials & interfaces.

[19]  Y. Anraku,et al.  Enhanced target recognition of nanoparticles by cocktail PEGylation with chains of varying lengths. , 2016, Chemical communications.

[20]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[21]  Lucas A Lane,et al.  SERS Nanoparticles in Medicine: From Label-Free Detection to Spectroscopic Tagging. , 2015, Chemical reviews.

[22]  T. Kiziltepe,et al.  Improved Peptide-Targeted Liposome Design Through Optimized Peptide Hydrophilicity, Ethylene Glycol Linker Length, and Peptide Density. , 2015, Journal of biomedical nanotechnology.

[23]  Jie Zheng,et al.  Clearance Pathways and Tumor Targeting of Imaging Nanoparticles. , 2015, ACS nano.

[24]  Chao Li,et al.  Gold Nanoclusters‐Based Nanoprobes for Simultaneous Fluorescence Imaging and Targeted Photodynamic Therapy with Superior Penetration and Retention Behavior in Tumors , 2015 .

[25]  N. Rosato,et al.  Molecular dynamics methods to predict peptide locations in membranes: LAH4 as a stringent test case. , 2015, Biochimica et biophysica acta.

[26]  E. Aboagye,et al.  RGD-targeted MnO nanoparticles as T1 contrast agents for cancer imaging - the effect of PEG length in vivo. , 2014, Journal of materials chemistry. B.

[27]  Jonathan D. Ashley,et al.  Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. , 2013, ACS nano.

[28]  Jonathan D. Ashley,et al.  A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. , 2013, ACS nano.

[29]  C. Toniolo,et al.  Membrane thickness and the mechanism of action of the short peptaibol trichogin GA IV. , 2013, Biochimica et biophysica acta.

[30]  Moreno Meneghetti,et al.  Plasmonic nanostructures for SERRS multiplexed identification of tumor-associated antigens. , 2012, Small.

[31]  Michael Leung,et al.  A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword , 2012, Advanced healthcare materials.

[32]  Philippe H. Hünenberger,et al.  A GROMOS Parameter Set for Vicinal Diether Functions: Properties of Polyethyleneoxide and Polyethyleneglycol. , 2012, Journal of chemical theory and computation.

[33]  M. Meneghetti,et al.  Exploring How to Increase the Brightness of Surface‐Enhanced Raman Spectroscopy Nanolabels: The Effect of the Raman‐Active Molecules and of the Label Size , 2012 .

[34]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[35]  K. Kataoka,et al.  Effect of integrin targeting and PEG shielding on polyplex micelle internalization studied by live-cell imaging. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[37]  C. Mazzuca,et al.  Fluorescence spectroscopy and molecular dynamics simulations in studies on the mechanism of membrane destabilization by antimicrobial peptides , 2011, Cellular and Molecular Life Sciences.

[38]  Carlo Scolastico,et al.  Cyclic RGD functionalized gold nanoparticles for tumor targeting. , 2011, Bioconjugate chemistry.

[39]  J. Benoit,et al.  The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. , 2010, Nanomedicine.

[40]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[41]  Shuming Nie,et al.  Understanding and overcoming major barriers in cancer nanomedicine. , 2010, Nanomedicine.

[42]  H. Kessler,et al.  Ligands for mapping alphavbeta3-integrin expression in vivo. , 2009, Accounts of chemical research.

[43]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[44]  P. Cummings,et al.  Molecular simulations of stretching gold nanowires in solvents , 2007, Nanotechnology.

[45]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[46]  M. Meneghetti,et al.  Laser ablation synthesis of gold nanoparticles in organic solvents. , 2006, The journal of physical chemistry. B.

[47]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[48]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[49]  R. Hwang,et al.  The role of integrins in tumor angiogenesis. , 2004, Hematology/oncology clinics of North America.

[50]  Robert Gurny,et al.  Current methods for attaching targeting ligands to liposomes and nanoparticles. , 2004, Journal of pharmaceutical sciences.

[51]  M. Chelli,et al.  On‐resin head‐to‐tail cyclization of cyclotetrapeptides: optimization of crucial parameters , 2004, Journal of peptide science : an official publication of the European Peptide Society.

[52]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[53]  H. Sawai,et al.  Alteration of Integrin Expression by Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Human Pancreatic Cancer Cells , 2003, Pancreas.

[54]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[55]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[56]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[57]  B. Borisch,et al.  Integrin αvβ3 Expression in Colon Carcinoma Correlates with Survival , 2001, Modern Pathology.

[58]  R. Weissleder.  A clearer vision for in vivo imaging , 2001, Nature Biotechnology.

[59]  F. Veronese.  Peptide and protein PEGylation: a review of problems and solutions. , 2001, Biomaterials.

[60]  Horst Kessler,et al.  Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy , 1997 .

[61]  S. Goodman,et al.  Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists , 1996 .

[62]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[63]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[64]  D. Cheresh,et al.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.

[65]  Joseph D. Andrade,et al.  Protein—surface interactions in the presence of polyethylene oxide , 1991 .

[66]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[67]  L. Litti,et al.  A surface enhanced Raman scattering based colloid nanosensor for developing therapeutic drug monitoring. , 2019, Journal of colloid and interface science.

[68]  Scott E McNeil,et al.  Nanomaterial standards for efficacy and toxicity assessment. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[69]  J. Pilch,et al.  Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. , 2002, The Journal of biological chemistry.

[70]  B. Borisch,et al.  Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. , 2001, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[71]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .